Dechra Pharmaceuticals plc Rating Reiterated by N+1 Singer (DPH)
Dechra Pharmaceuticals plc (LON:DPH)‘s stock had its “buy” rating reiterated by stock analysts at N+1 Singer in a report issued on Tuesday. They currently have a GBX 760 ($13.04) price target on the stock. N+1 Singer’s price objective would suggest a potential upside of 3.68% from the company’s current price.
Shares of Dechra Pharmaceuticals plc (LON:DPH) opened at 726.00 on Tuesday. Dechra Pharmaceuticals plc has a 1-year low of GBX 655.00 and a 1-year high of GBX 755.00. The stock’s 50-day moving average is GBX 708. and its 200-day moving average is GBX 696.7. The company’s market cap is £633.1 million.
A number of other firms have also recently commented on DPH. Analysts at FinnCap reiterated a “buy” rating on shares of Dechra Pharmaceuticals plc in a research note on Tuesday. They now have a GBX 800 ($13.72) price target on the stock. Finally, analysts at Investec raised their price target on shares of Dechra Pharmaceuticals plc from GBX 787 ($13.50) to GBX 842 ($14.44) in a research note on Wednesday, June 11th. They now have a “buy” rating on the stock. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Dechra Pharmaceuticals plc has a consensus rating of “Buy” and an average target price of GBX 781 ($13.40).
Dechra Pharmaceuticals PLC is a United Kingdom-based veterinary pharmaceutical company. The Company is engaged in developing, manufacturing, distributing, selling and marketing of animal products to the veterinary industry.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.